The lower rating came from HSBC, which cited too much optimism around its new weight-loss pill, and the strength of Novo ...

President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare ...

Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

The drug company Eli Lilly is suing four telehealth companies for allegedly selling copies made by compounding pharmacies of ...

Shares in pharmaceuticals firm Eli Lilly (LLY) rose today after it said it was suing companies ripping off its weight-loss ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

That's why many drugmakers have been looking to develop an effective oral weight loss option, and Eli Lilly might have just done it. In a phase 3 study, orforglipron, a once-daily weight ...

Eli Lilly (NYSE: LLY) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in ...